Economic Evaluation of a Universal Childhood Pneumococcal Conjugate Vaccination Strategy in Ireland
| Autor: | Michael J. Barry, Cara Usher, Darina O'Flanagan, Lesley Tilson, Howard Johnson, Suzanne Cotter, Karina Butler, Fiona O'Hare, John Fitzsimons |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Immunity Herd Male Cost effectiveness Cost-Benefit Analysis Child Welfare PCV7 vaccine Pneumococcal Infections Pneumococcal conjugate vaccine Herd immunity Pneumococcal Vaccines pneumococcal conjugate vaccination Sepsis Confidence Intervals Humans herd immunity Medicine Child cost-effectiveness Immunization Schedule Aged childhood Aged 80 and over Models Statistical Vaccines Conjugate Meningitis Pneumococcal business.industry Health Policy Vaccination Pneumococcal conjugate vaccination Public Health Environmental and Occupational Health Infant Pneumonia Middle Aged Models Economic Child Preschool Immunology Cohort Economic evaluation Female Quality-Adjusted Life Years business Ireland Program Evaluation Demography medicine.drug |
| Zdroj: | Value in Health. 11:898-903 |
| ISSN: | 1098-3015 |
| Popis: | Objective To evaluate the cost-effectiveness of implementing a universal infant 7-valent pneumococcal conjugate vaccine (PCV7) vaccination program in the Irish health-care setting from the health-care payers' perspective. Methods A model was constructed in MS Excel to follow a cohort of vaccinated and unvaccinated individuals from birth over a 5-year period. The reduction in events that would be associated with PCV7 vaccination and the mortality and cost resulting from these events were analyzed. In a separate submodel, the effect of herd immunity was investigated. Results Implementing a PCV7 vaccine program in Ireland in a birth cohort of 61,000 infants would be expected to prevent 7703 cases of pneumococcal-related infections over 5 years, resulting in costs avoided of €2.05 million increasing to €4.6 million if the effect of herd immunity was included. The baseline incremental cost-effectiveness ratio was €249,591/life years gained (LYG), which reduced to €5997/LYG when the effect of herd immunity was included. Conclusions A universal infant pneumococcal conjugate vaccination could be considered highly cost-effective in the Irish health-care setting from a health-care payers' perspective, if viewed in terms of the herd immunity effect. The results of this study have positive ramifications for countries in the early stages of health technology assessment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect